Discontinuation of Sanofi’s C. difficile Vaccine Program presents an opportunity for Pfizer and Valneva, observes GlobalData
On December 1 2017, Sanofi Pasteur announced its intention to discontinue the Phase III development program for its Clostridium difficile vaccine. The vaccine was on ...
Continue Reading →
